First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: TG Therapeutics: the setup is constructive — Briumvi quarterly prescription trends (TRx and NBRx data from IQVIA) and market share gains in relapsing MS segment
growth - Attracts growth investors focused on commercial-stage biotech with single-product revenue inflection.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for growth…
Watch on earnings: Briumvi weekly prescription data (NBRx and TRx) from Symphony Health or IQVIA, Quarterly net product revenue and gross-to-net percentage (rebates, discounts, co-pay assistance), Operating cash flow trajectory and quarters to sustained positive OCF.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $941M to $1.2B as briumvi quarterly prescription trends (trx and nbrx data from iqvia) and market share gains in relapsing ms segment.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.